Low-density lipoprotein cholesterol goal attainment in patients with clinical evidence of familial hypercholesterolemia and elevated Lp(a)

被引:3
|
作者
Schwarz, Andrea [1 ,2 ,3 ,4 ,5 ]
Demuth, Ilja [1 ,2 ,3 ,4 ,6 ]
Landmesser, Ulf [7 ,8 ,9 ]
Haghikia, Arash [7 ,8 ,9 ]
Konig, Maximilian [1 ,2 ,3 ,4 ]
Steinhagen-Thiessen, Elisabeth [1 ,2 ,3 ,4 ,10 ]
机构
[1] Charite Univ Med Berlin, Dept Endocrinol & Metab Dis, Including Div Lipid Metab, Augustenburger Pl 1, D-13353 Berlin, Germany
[2] Charite Univ Med Berlin, Augustenburger Pl 1, D-13353 Berlin, Germany
[3] Free Univ Berlin, Augustenburger Pl 1, D-13353 Berlin, Germany
[4] Humboldt Univ, Biol Aging Working Grp, Augustenburger Pl 1, D-13353 Berlin, Germany
[5] Charite Univ Med Berlin, Div Cardiol, Dept Pediat, Berlin, Germany
[6] BCRT Berlin Inst Hlth Ctr Regenerat Therapies, Berlin, Germany
[7] Charith Univ Med Berlin, Berlin Inst Hlth, Berlin, Germany
[8] Charite Univ Med Berlin, Dept Cardiol, Campus Benjamin Franklin, Berlin, Germany
[9] German Ctr Cardiovasc Res DZHK, Partner Site Berlin, Berlin, Germany
[10] Univ Rostock, Inst Clin Chem & Lab Med, Rostock, Germany
关键词
LDL-cholesterol; Treatment goal achievement; Familial hypercholesterolemia; Lipoprotein (a); Coronary artery disease; Lipid-lowering treatment; Family history; LIPID-MODIFYING THERAPY; CARDIOVASCULAR RISK; HEART-DISEASE; ASSOCIATION; EZETIMIBE; HISTORY; ATORVASTATIN; SIMVASTATIN; GUIDELINE; DIAGNOSIS;
D O I
10.1186/s12944-022-01708-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background Although potent lipid-lowering therapies are available, patients commonly fall short of recommended low-density lipoprotein cholesterol (LDL-C) levels. The aim of this study was to examine the relationship between familial hypercholesterolemia (FH) and elevated lipoprotein(a) [Lp(a)] and LDL-C goal attainment, as well as the prevalence and severity of coronary artery disease (CAD). Moreover, we characterized patients failing to meet recommended LDL-C goals. Methods We performed a cross-sectional analysis in a cohort of patients undergoing cardiac catheterization. Clinical FH was determined by the Dutch Clinical Lipid Network Score, and Lp(a) >= 50 mg/dL (approximate to 107 nmol/L) was considered elevated. Results A total of 838 participants were included. Overall, the prevalence of CAD was 72%, and 62% received lipid-lowering treatment. The prevalence of clinical FH (probable and definite FH) was 4%, and 19% had elevated Lp(a) levels. With 35%, LDL-C goal attainment was generally poor. Among the participants with clinical FH, none reached their LDL-C target. Among patients with elevated Lp(a), LDL-C target achievement was only 28%. The prevalence and severity of CAD were higher in participants with clinical FH (86% prevalence) and elevated Lp(a) (80% prevalence). Conclusion Most participants failed to meet their individual LDL-C goals according to the ESC 2016 and 2019 guidelines. In particular, high-risk patients with clinical FH or elevated Lp(a) rarely met their target for LDL-C. The identification of these patients and more intense treatment approaches are crucial for the improvement of CAD primary and secondary prevention.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] EVINACUMAB MARKEDLY REDUCES LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN ADOLESCENT PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
    Reeskamp, L. F.
    Greber-Platzer, S.
    Saheb, S.
    Stefanutti, C.
    Stroes, E. S. G.
    Ali, S.
    Banerjee, P.
    Pordy, R.
    Zhao, J.
    Raal, F. J.
    ATHEROSCLEROSIS, 2021, 331 : E49 - E50
  • [22] Low-density lipoprotein cholesterol bulk is the pivotal determinant of atherosclerosis in familial hypercholesterolemia
    Raal, FJ
    Pilcher, GJ
    Waisberg, R
    Buthelezi, EP
    Veller, MG
    Joffe, BI
    AMERICAN JOURNAL OF CARDIOLOGY, 1999, 83 (09): : 1330 - 1333
  • [23] Ezetimibe significantly reduces low-density lipoprotein cholesterol in homozygous familial hypercholesterolemia
    Gagne, C
    Gaudet, D
    Bruckert, E
    Ponsonnet, D
    Lipka, L
    LeBeaut, A
    Suresh, R
    Abreu, P
    Veltri, E
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (05) : 227A - 227A
  • [24] Systematic Review of Low-Density Lipoprotein Cholesterol Apheresis for the Treatment of Familial Hypercholesterolemia
    Wang, Anthony
    Richhariya, Akshara
    Gandra, Shravanthi R.
    Calimlim, Brian
    Kim, Lisa
    Quek, Ruben G. W.
    Nordyke, Robert J.
    Toth, Peter P.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2016, 5 (07):
  • [25] MODELLING THE US POPULATION HEALTH BENEFITS OF FURTHER LOW-DENSITY LIPOPROTEIN CHOLESTEROL REDUCTION WITH ALIROCUMAB AMONG ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL
    Sanchez, Robert
    Nasir, Khurram
    Klimchak, Alexa
    Kuznik, Andreas
    Joulain, Florence
    Briggs, Andrew
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 66 - 66
  • [26] LOW-DENSITY LIPOPROTEIN METABOLISM IN THE NORMAL TO MODERATELY ELEVATED RANGE OF PLASMA-CHOLESTEROL - COMPARISONS WITH FAMILIAL HYPERCHOLESTEROLEMIA
    SIMONS, LA
    BALASUBRAMANIAM, S
    HOLLAND, J
    JOURNAL OF LIPID RESEARCH, 1983, 24 (02) : 192 - 199
  • [27] LOSS OF EARLY GAINS IN LOW-DENSITY LIPOPROTEIN CHOLESTEROL GOAL ATTAINMENT AMONG HIGH RISK PATIENTS
    Foody, Joanne M.
    Sajjan, Shiva
    Hu, Henry
    Ramey, Dena R.
    Neff, David
    Tershakovec, Andrew M.
    Tomassini, Joanne E.
    Tunceli, Kaan
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (10)
  • [28] LOW-DENSITY LIPOPROTEIN CHOLESTEROL GOAL ATTAINMENT BASED ON 2015 KOREAN DYSLIPIDEMIA GUIDELINES
    Kim, E.
    Han, S.
    Rane, P. P.
    Qian, Y.
    Suh, H. S.
    VALUE IN HEALTH, 2018, 21 : S67 - S67
  • [29] Attainment of Low-Density Lipoprotein Cholesterol Treatment Target in Familial Hypercholesterolemia Patients: A Model Exploring Efficacy of Current and Novel Lipid Lowering Therapies
    Hartgers, Merel L.
    Besseling, Joost
    Hovingh, G. K.
    CIRCULATION, 2016, 134
  • [30] The Low-Density Lipoprotein Receptor Genotype Is a Significant Determinant of the Rebound in Low-Density Lipoprotein Cholesterol Concentration After Lipoprotein Apheresis Among Patients With Homozygous Familial Hypercholesterolemia
    Drouin-Chartier, Jean-Philippe
    Tremblay, Andre J.
    Bergeron, Jean
    Lamarche, Benoit
    Couture, Patrick
    CIRCULATION, 2017, 136 (09) : 880 - 882